Survodutide
InvestigationalAlso known as: BI 456906, Boehringer Ingelheim dual agonist
Metabolic & Weight ManagementLast reviewed: April 28, 2026
A dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim for obesity and metabolic liver disease (MASH/NASH). Unlike tirzepatide (GIP/GLP-1), survodutide activates the glucagon receptor alongside GLP-1, which increases energy expenditure and hepatic fat oxidation. Phase 2 trials showed up to 18.7% weight loss at 46 weeks and significant liver fat reduction, making it a leading candidate for MASH treatment.
Mechanism of Action
Dual agonism of glucagon and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying. Glucagon activation increases hepatic fat oxidation, energy expenditure, and thermogenesis. The combination targets both caloric intake and energy output, with particular benefit for liver fat reduction — a mechanism not shared by pure GLP-1 agonists.
Common Uses
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Metabolic syndrome
- Liver fat reduction
Known Risks
- GI side effects (nausea, vomiting, diarrhea) — common in GLP-1 class
- Potential blood sugar effects from glucagon activation
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
Regulatory Status
Currently in Phase 3 trials for obesity (SYNCHRONIZE program) and MASH (LIVERAGE program). Phase 2 data showed 18.7% weight loss at 46 weeks and 87% relative reduction in liver fat. Potential FDA submission expected 2027. Represents a differentiated mechanism from tirzepatide and semaglutide.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (investigational)
Typical Dose
Up to 6.0 mg (in clinical trials)
Frequency
Once weekly
Cycle Length
Ongoing — not commercially available
Not available outside clinical trials. The glucagon component differentiates it from other GLP-1 drugs and may offer unique benefits for liver disease. Check clinicaltrials.gov for active SYNCHRONIZE and LIVERAGE trials.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.